【摘要】 目的 〖JP2〗探讨血管内皮生长因子（VEGF）联合血清肿瘤标志物对肺癌早期诊断意义。 方法 2008年1月-〖JP〗2009年8月收治的92例患者中肺癌患者64例，采集静脉血清标本采用酶联免疫法检测其VEGF水平。 结果 64例肺癌与28例非肺癌患者VEGF表达水平分别为（255.72±566.00）、（299.46±795.8） pg/mL，两者比较无统计学意义（Pgt;0.05）；43例中晚期肺癌VEGF值（125.07±68.2） pg/mL，表达显著高于12例早期肺癌（196.00±260.60） pg/mL （Plt;0.05）；CEA与CYFRA21-1的表达对判断26例发生胸膜转移的肺癌有统计学意义（Plt;0.05）。 结论 结合血清VEGF水平和常规肿瘤标志物，可评估现状及临床分期，VEGF结合CEA与CYFRA21-1表达水平为预测肺癌患者早期发生胸膜转移提供理论依据。【Abstract】 Objective To evaluate the effect of combined detection value of serum vascular endothelial growth factor (VEGF) and tumor markers on early diagnosis of lung cancer. Method Intravenous serum levels of VEGF and tumor markers were assayed by ELISA in 92 patients including 64 lung cancer from January 2008 to August 2009. Results The difference in serum levels of VEGF between the 64 patients with lung cancer [(255.72±566.0) pg/mL] and 28 health adult [(299.46±795.8) pg/mL] was not significant (Pgt;0.05). The level of VEGF in 43 patients with middle and late lung cancer [(125.07±68.2) pg/mL] was significantly higher than that in the 12 patients with early lung cancer [(196.00±260.60) pg/mL] (Plt;0.05). There were statistical significance in expression of serum CEA and CYFRA21-1 on diagnosis in 26 patients having lung cancer with early metastasis pleural fluid (Plt;0.05). Conclusion Combined diagnostic of serum VEGF and tumor markers can assess the state of an illness and clinical stage, and the serum levels of serum VEGF,CEA and CYFRA21-1 may be a good predictor for lung cancer with early metastasis pleural fluid.